Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00753870
Other study ID # 07-2060 (GCRC 2670)
Secondary ID P50HL084934-01
Status Terminated
Phase Phase 1
First received September 15, 2008
Last updated April 14, 2011
Start date August 2008
Est. completion date December 2009

Study information

Verified date April 2011
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Food and Drug AdministrationUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Endotoxin is a component of outdoor air pollution, an air contaminant found in a number of different workplaces, and is even found in homes. The endotoxin used for this study is obtained from the National Institutes of Health, and is called "Clinical Center Reference Endotoxin", or CCRE. The purpose of this Phase 1 research study is to identify a dose of inhaled endotoxin that is safe (does not cause prolonged cough, shortness of breath or other problems), but causes changes in sputum cell samples that the scientists can measure. Phase 1 research studies like this one are not intended to be a treatment, but are a scientific investigation. Eventually, with these types of studies we will be able to examine why some people are more sensitive to endotoxin. Scientists at other universities have found that while most people do not have a considerable lung response to endotoxin at doses as high as 60,000 EU (endotoxin units), a few respond to as little as a total dose of 4500 EU. Our study is designed to identify if using a dose of 20,000 EU causes changes in the lung cells but does not cause symptoms in our study subjects. In our previous studies in our lab, using an endotoxin from another source, we have used higher doses (15,000 EUs) in subjects with asthma with no major problems, and we have used 10,000 EUs of CCRE in subjects who are current smokers without seeing any problems.


Description:

We are looking for people who currently smoke a minimum of a half a pack of cigarettes each day. You must not have any other health problems, be pregnant or nursing a baby, or actively trying to become pregnant or to father a child.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date December 2009
Est. primary completion date December 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- current smoker

- healthy

Exclusion Criteria:

- no asthma

- no chronic health conditions

- no daily cough

- not pregnant or nursing a baby

- not actively trying to get pregnant or father a child

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Biological:
CCRE inhalation
20,000 EU CCRE given as a one-time challenge

Locations

Country Name City State
United States UNC Center for Environmental Medicine, Asthma and Lung Biology Chapel Hill North Carolina

Sponsors (3)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To identify a dose of inhaled CCRE that is well tolerated and that induces measurable increases in neutrophil content of induced sputum that can be employed to screen large populations for susceptibility to the inflammatory effect of inhaled endotoxin. post exposure Yes
See also
  Status Clinical Trial Phase
Withdrawn NCT00159302 - Biomarkers of iNOS Activity in COPD, Asthma, Healthy Control
Completed NCT03728530 - Effect Of Deep Breathing Exercises In Smokers N/A
Completed NCT02089308 - Nicotine Patch - Bioequivalence Study Phase 1
Completed NCT01574898 - Pilot Pharmacokinetic Study of New Nicotine Lozenge Formulations Phase 1
Completed NCT01658215 - Nicotine Patch - Multidose Bioequivalence Study Phase 1
Completed NCT01658202 - Nicotine Patch Bioequivalence Study Phase 1
Completed NCT01164072 - Efficacy and Safety of an Electronic Nicotine Delivery Device (E-Cigarette) N/A
Completed NCT01188239 - A Structured Protocol to Evaluate Efficacy and Safety of a Popular Electronic Nicotine Delivery Device (E-Cigarette) Efficacy and Safety of a Popular Electronic Nicotine Delivery Device (E-Cigarette) N/A
Completed NCT01194583 - Efficacy and Safety of an Electronic Nicotine Delivery Device (E-Cigarette) Without Nicotine Cartridges N/A

External Links